as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹976.2
Change
-33.5 (-3.32%)
Open
₹1,009.0
Prev. Close
₹1,009.7
Day High
₹1,020.45
Day Low
₹960.05
Volume Analysis
Traded
103,338
Delivered
58,242
Delivery %
56.36%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (30.0%)
Weaknesses (2)
- •Low return on equity (9.99%)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year EPS growth (26.9%)
- •Strong 3-year revenue growth (23.6%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,071.49 | ₹1,045.97 | ₹1,011.09 | ₹985.57 | ₹950.69 | ₹925.17 | ₹890.29 |
| Fibonacci | ₹1,045.97 | ₹1,022.9 | ₹1,008.64 | ₹985.57 | ₹962.5 | ₹948.24 | ₹925.17 |
| Camarilla | ₹992.81 | ₹987.27 | ₹981.74 | ₹985.57 | ₹970.66 | ₹965.13 | ₹959.59 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+139.91%
1 Week
-8.96%
1 Month
+7.89%
3 Months
+6.97%
6 Months
+28.18%
1 Year
+149.35%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹125.26
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
13.46%
Net margin 14.24% × asset turnover 0.7x × equity multiplier 1.35x
Company Overview
Sector
Healthcare
Market Cap
₹2,172 Cr
P/E (TTM)
50.7
ROE
9.99%
Book Value
₹156.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 20 Nov 2026. Not investment advice.
TopFund Analysis
Sakar Healthcare Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 65/100. The strongest factor is Financial Strength (100/100), while Valuation (11/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (30.0%); low return on equity (9.99%); promoter holding is falling. FII holding has been falling.
TopFund Score — Fundamentals Quality
65/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- +Company is expected to give good quarter
- +Company has delivered good profit growth of 23.1% CAGR over last 5 years
- −Stock is trading at 6.28 times its book value
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Promoter holding has decreased over last quarter: -0.82%
- −Company has a low return on equity of 7.50% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Sakar Healthcare Q2 FY27 revenue rose 52% to ₹87.4 crore; EBITDA up 114%, PAT up 149%, oncology expanded.
Q2FY27 earnings conference call audio recording uploaded on October 27, 2026; transcript to follow.
Sakar Healthcare shared Q2 and H1FY27 results: revenue up 52%, EBITDA 114%, PAT 149%.
Sakar reported Q2/H1 FY27 results; revenue up 53%, EBITDA 114%, PAT 149%, with commercial supplies starting.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 34 | 37 | 43 | 41 | 43 | 43 | 50 | 53 | 58 | 70 | 71 | 73 | 87 |
| Expenses + | 25 | 28 | 32 | 30 | 31 | 32 | 35 | 40 | 46 | 52 | 45 | 52 | 63 |
| Operating Profit | 9 | 9 | 11 | 11 | 12 | 12 | 16 | 13 | 11 | 19 | 26 | 21 | 24 |
| OPM % | 27.0% | 24.0% | 25.0% | 26.0% | 27.0% | 27.0% | 31.0% | 24.0% | 20.0% | 26.0% | 37.0% | 29.0% | 28.0% |
| Other Income + | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 |
| Interest | 2 | 2 | 2 | 1 | 2 | 1 | 4 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 7 | 7 |
| Profit before tax | 4 | 3 | 5 | 5 | 5 | 5 | 6 | 5 | 5 | 11 | 18 | 15 | 16 |
| Tax % | 13.0% | 31.0% | 35.0% | 49.0% | 6.0% | 17.0% | 8.0% | 13.0% | 15.0% | 6.0% | 39.0% | 29.0% | 29.0% |
| Net Profit + | 4 | 2 | 3 | 2 | 5 | 5 | 6 | 5 | 5 | 10 | 11 | 10 | 11 |
| EPS in Rs | 2 | 1 | 1 | 1 | 2 | 2 | 3 | 2 | 2 | 5 | 5 | 5 | 5 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 11 | 11 | 6 | 6 | 26 | 17 | 17 | 28 | 35 | 62 | 42 | 38 | 52 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 35 | 41 | 44 | 53 | 68 | 83 | 95 | 128 | 133 | 153 | 178 | 251 | 302 |
| Expenses + | 27 | 33 | 34 | 40 | 51 | 63 | 72 | 99 | 100 | 115 | 128 | 182 | 211 |
| Operating Profit | 8 | 8 | 10 | 13 | 17 | 20 | 23 | 29 | 33 | 38 | 50 | 69 | 90 |
| OPM % | 22.0% | 20.0% | 23.0% | 24.0% | 25.0% | 24.0% | 24.0% | 23.0% | 25.0% | 25.0% | 28.0% | 27.0% | 30.0% |
| Other Income + | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 2 | 5 | 3 | 1 | 2 | 2 |
| Interest | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 6 | 8 | 9 | 8 | 8 |
| Depreciation | 2 | 3 | 3 | 4 | 6 | 7 | 8 | 10 | 15 | 18 | 21 | 24 | 25 |
| Profit before tax | 2 | 3 | 5 | 6 | 9 | 12 | 13 | 19 | 17 | 16 | 22 | 40 | 60 |
| Tax % | 24.0% | 22.0% | 30.0% | 38.0% | 28.0% | 21.0% | 19.0% | 20.0% | 24.0% | 27.0% | 19.0% | 23.0% | — |
| Net Profit + | 2 | 2 | 3 | 4 | 7 | 10 | 11 | 15 | 13 | 12 | 18 | 30 | 43 |
| EPS in Rs | 2 | 3 | 3 | 3 | 4 | 6 | 7 | 9 | 7 | 5 | 8 | 14 | 19 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | 18 | 18 | 7 | 20 | 29 | — | 14 | 35 | 4 | 15 | 16 | 42 | 48 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 7 | 11 | 25 | 39 | 57 | 66 | 83 | 110 | 154 | 241 | 264 | 302 | 324 |
| Borrowings + | 25 | 22 | 24 | 11 | 11 | 17 | 43 | 93 | 119 | 79 | 86 | 71 | 46 |
| Other Liabilities + | 11 | 10 | 11 | 18 | 15 | 17 | 37 | 47 | 44 | 47 | 43 | 86 | 124 |
| Total Liabilities | 50 | 51 | 71 | 81 | 97 | 115 | 178 | 268 | 336 | 389 | 415 | 481 | 516 |
| Fixed Assets + | 36 | 37 | 49 | 53 | 64 | 66 | 69 | 205 | 267 | 314 | 309 | 326 | 334 |
| CWIP | 0 | 0 | 0 | 0 | 9 | 13 | 49 | 1 | 6 | 0 | 17 | 4 | 6 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 3 | 0 | 0 | 0 | 0 |
| Other Assets + | 14 | 14 | 22 | 28 | 25 | 36 | 60 | 55 | 60 | 74 | 90 | 151 | 176 |
| Total Assets | 50 | 51 | 71 | 81 | 97 | 115 | 178 | 268 | 336 | 389 | 415 | 481 | 516 |
| Equity Capital | 8 | 8 | 11 | 12 | 15 | 15 | 16 | 17 | 19 | 22 | 22 | 22 | 22 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 4 | 9 | 2 | 5 | 16 | 19 | 15 | 36 | 33 | 24 | 34 | 49 |
| Cash from Investing Activity + | -1 | -4 | -14 | -8 | -25 | -22 | -47 | -90 | -74 | -52 | -31 | -28 |
| Cash from Financing Activity + | -3 | -6 | 13 | -13 | 9 | 3 | 32 | 55 | 41 | 27 | -3 | -21 |
| Net Cash Flow | 1 | -1 | 0 | -16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | 4 | 5 | -13 | -4 | -9 | -4 | -32 | -62 | -49 | -35 | 2 | 21 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 60 | 117 | 30 | 51 | 104 | 110 | 67 | 120 | 113 | 72 | 73 | 77 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 22.47% | 22.71% | 22.71% | 22.8% | 21.96% | 21.85% | 22.48% | 22.41% | 22.73% | 22.87% | 23.98% | 24.04% |
| Promoters | 53.15% | 53.15% | 53.15% | 53.15% | 53.58% | 53.58% | 52.86% | 52.86% | 52.86% | 52.86% | 52.52% | 51.7% |
| FII | 13.76% | 13.52% | 13.52% | 13.42% | 13.58% | 13.61% | 13.41% | 13.31% | 13.05% | 12.94% | 12.13% | 12.34% |
| DII | 10.62% | 10.62% | 10.62% | 10.62% | 10.88% | 10.97% | 11.25% | 11.43% | 11.36% | 11.32% | 11.37% | 11.92% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Sakar Healthcare Limited (this stock) | 2,172 | 50.7 | 6.26 | 9.99% |
| Panacea Biotec Ltd | 2,171 | — | 2.6 | -2.42% |
| Dishman Carbo Amcis Ltd | 2,183 | 151.0 | 0.33 | 1.58% |
| Sai Parenterals Limited | 2,189 | 87.8 | 4.42 | 4.88% |
| Vimta Labs Limited | 2,230 | 36.7 | 6.46 | 13.5% |
| Indoco Remedies Ltd. | 2,079 | — | 2.03 | -9.36% |
| Windlas Biotech Limited | 2,067 | 31.1 | 3.64 | 12.2% |
Which Mutual Funds Hold Sakar Healthcare Limited?
Frequently Asked Questions about Sakar Healthcare Limited
Sakar Healthcare Limited (SAKAR) closed at ₹976.2 on NSE on 19 November 2026, down 33.5 (3.32%) from the previous close.
Sakar Healthcare Limited trades on the NSE (National Stock Exchange of India) under the symbol SAKAR.
Sakar Healthcare Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 50.7.
Sakar Healthcare Limited has a dividend yield of 0.0%.
Sakar Healthcare Limited's 52-week high is ₹1,230.0 and its 52-week low is ₹352.0.
Sakar Healthcare Limited has a market capitalisation of ₹2,172 crore.
Sakar Healthcare Limited has a TopFund Quality Score of 65/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Sakar Healthcare Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.